Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer | OncLive

Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer

September 7, 2020

In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.

Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour.

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by GlaxoSmithKline, we passed the mic to Thomas Herzog, MD, a professor of obstetrics and gynecology and deputy director at University of Cincinnati Cancer Institute, and Kathleen Moore, MD, director of the Oklahoma TSET Phase I Clinical Trials Program, and associate professor in the Section of Gynecologic Oncology, Jim and Christy Everest Endowed Chair in Cancer Research, director of the Gynecologic Oncology Fellowship Program, associate director of Clinical Research, and medical director of the Clinical Trials Office, at Stephenson Cancer Center, to discuss the evidence in support of PARP inhibition in patients with newly diagnosed advanced ovarian cancer.

In our exclusive interview, Dr. Herzog and Dr. Moore reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.

Sponsored by:


x